Solvay Group holds 93.1% of Innogenetics shares

Offer on Innogenetics shares is extended from 22 October to 12 November

20-Oct-2008 - Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group announced that it will acquire 2,714,371 additional shares of Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The shares were offered to Solvay ...

Solvay Pharmaceuticals acquires Innogenetics

Solvay Group holds 84.3% of Innogenetics shares

11-Sep-2008 - Solvay Pharmaceuticals S.A., a subsidiary of the Solvay Group, announced that it succeeded to acquire Innogenetics N.V. in a cash transaction valued at EUR 6.5 per share, representing EUR 200.7 million for 100% of the Innogenetics shares. The offer on Innogenetics shares ran from 12 August to 5 ...

Innogenetics grants GlaxoSmithKline Biologicals a license for use of HPV SPF10 genotyping technology in clinical studies on HPV

03-Jul-2008 - Innogenetics announced that it has granted GlaxoSmithKline Biologicals (GSK) a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological human papillomavirus (HPV) vaccine studies. Innogenetics will receive royalties for each individual ...

Innogenetics achieves CE mark for new human papillomavirus (HPV) genotyping test

04-Jun-2008 - Innogenetics announced that it has received CE marking for its new and expanded HPV genotyping test, the INNO-LiPA HPV Genotyping Extra. The new generation kit allows the genotyping of 28 different HPV genotypes, of which 18 are high-risk types for the possible development of cervical cancer. The ...

Innogenetics announces definitive closure of GENimmune

03-Jun-2008 - Innogenetics announced the final phase of its restructuring plan for the pharma division of GENimmune. In accordance with the collective labor agreement signed on May 8 with its social partners, the remaining 5 labor contracts will shortly be terminated.

Solvay Pharmaceuticals S.A. launches friendly bid to acquire Innogenetics

Building on a successful R&D co-operation

29-Apr-2008 - Solvay Pharmaceuticals S.A., a subsidiary of Solvay, and Innogenetics N.V. jointly announced that Solvay Pharmaceuticals S.A. will make a conditional tender offer to acquire Innogenetics in a cash transaction valued at EUR 5.75 per share. Solvay initially entered into an R&D co-operation with ...

Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery

10-Apr-2008 - Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug development activities. As of 2002, the original ...

Innogenetics announces the intention to restructure its subsidiary GENimmune

14-Feb-2008 - Last year, Innogenetics decided to focus on the development and sales of diagnostic products, and GENimmune N.V. was incorporated as a fully owned subsidiary. GENimmune obtained assets of Innogenetics in the field of drug development. The strategy of Innogenetics is to focus solely on ...

Innogenetics secures key patent for hepatitis B drug resistance testing

08-Feb-2008 - Innogenetics announced that the United States Patent Office has granted a key patent for hepatitis B drug resistance testing. This is the first granted US patent covering a critical mutation leading to hepatitis B viral drug resistance. US patent 7,313,357 covers an HBV virus with the YMDD ...

GENimmune receives Orphan Medicinal Product Designation from European Commission for its hepatitis C monoclonal antibody

13-Dec-2007 - GENimmune, the newly created biopharmaceutical subsidiary of Innogenetics, announced that its candidate hepatitis C monoclonal antibody has been granted Orphan Medicinal Product Designation by the European Commission. The product is under development for the prevention of hepatitis C virus ...